The generic version of Aczone could become available after the 18th of November, 2033, when the last patent expires.
Aczone is used for the topical treatment of acne vulgaris. Its active ingredient, dapsone, is effective in managing this skin condition.
Aczone holds three drug patents, with none expired yet. The expiration date for these patents is November 18th, 2033. To get more details on when the Aczone generic could potentially become available, refer to the patent details. Below are the details of the patents: